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Abstract The efﬁcacy of inﬂiximab, a chimeric antibody
against tumor necrosis factor-a used to treat patients with
rheumatoid arthritis (RA), tends to decrease as patients
develop human antichimeric antibody against inﬂiximab
(HACA). The clinical study reported here was designed to
evaluate the efﬁcacy of mizoribine (MZR) pulse therapy in
patients who show a reduced or insufﬁcient response to
inﬂiximab. Ten RA patients who had active arthritis despite
inﬂiximab therapy were treated with MZR pulse therapy at
a dose of 100 mg MZR and methotrexate (MTX) and the
disease activity assessed at baseline and at weeks 4–8,
12–16, and 20–24. The dose was increased to 150 mg in
those patients who showed an insufﬁcient response to
MZR. The mean 28-joint disease activity score (DAS28) at
weeks 12–16 and 20–24 of therapy was signiﬁcantly lower
than that at baseline. A moderate or good European League
against Rheumatism (EULAR) response was achieved in
seven patients (70%) at weeks 12–16 and in ﬁve patients
(50%) at weeks 20–24. The dose of 150 mg MZR was
effective in one of the three patients who showed an
insufﬁcient response to pulse therapy with 100 mg MZR.
Based on these results, we propose that MZR pulse therapy
should be attempted before the patient is switched to other
biologics.
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Introduction
Inﬂiximab is a chimeric anti-tumor necrosis factor-alpha
(TNF-a) monoclonal antibody that has proven effective in
patients with rheumatoid arthritis (RA) [1–3]. In Japan,
mizoribine (MZR; 4-carbamoyl-1-b-D-ribofuranosylimi-
dazolium) is used as an immunosuppressive agent in
patients undergoing renal transplantation and receiving
treatment for RA and lupus nephritis in Japan. This drug
inhibits inosine monophosphate dehydrogenase, a rate-
limiting enzyme in the de novo pathway of nucleic acid
synthesis, thereby inhibiting lymphocyte proliferation
[4, 5]. Mizoribine, which is usually used at a daily dose of
75–150 mg administered in three separate doses, is known
for its low rate of side effects [6], but it has been consid-
ered comparatively less effective than other disease-
modifying antirheumatic drugs (DMARDs) in patients with
RA. A correlation between the peak MZR blood concen-
tration and clinical response to the therapy has been
observed in patients with lupus nephritis [7]. It has also
been recently shown that a drug therapeutic regimen con-
sisting of 100–150 mg MZR once daily is more effective
than the three divided doses because the achieved blood
concentration was higher with the former [8]. Mizoribine
pulse therapy has also been found to be effective in patients
with RA who show an inadequate effect of methotrexate
(MTX) [9–11]. In the case of MZR pulse therapy, patients
receive MZR on one or two days of the week combined
with MTX. The basis of this combination therapy is that
MZR inhibits the synthesis of purines and MTX inhibits
primarily the synthesis of pyrimidines; consequently, both
drugs together inhibit the de novo pathway of nuclei acid
synthesis. As such, the combined use of these two drugs is
considered to inhibit lymphocyte proliferation more
effectively than either used solely (monotherapy) [12].
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therapy as additional therapy for nine patients who showed
an insufﬁcient effect of MTX. Five of the nine patients
responded to the combined MZR pulse ? MTX drug
therapeutic regimen within 20 weeks. Kohriyama et al.
[10] and Murai et al. [11] also reported the efﬁcacy of
MZR pulse therapy as additional therapy in patients
showing an inadequate effect of MTX.
An important problem associated with the use of inf-
liximab in therapeutic drug regimens is that its efﬁcacy
often decreases during prolonged treatment. In Japan, the
approved dose of inﬂiximab is up to 3 mg/kg, or 200
mg/body, and that of MTX is up to 8 mg/week. Insufﬁcient
doses of these drugs may contribute to a decrease in the
clinical efﬁcacy of inﬂiximab. The objective of this clinical
study was to evaluate the efﬁcacy of MZR pulse therapy in
patients who show reduced or insufﬁcient response to
inﬂiximab.
Patients and methods
Background of the patients
Ten RA patients treated with inﬂiximab between 2005 and
2008 at Tsukuba University Hospital were enrolled in this
study. Of these, eight showed a reduced response to inf-
liximab (=high disease activity despite the clinical response
to inﬂiximab by week 30 of treatment), and two showed an
insufﬁcient response to inﬂiximab (=no clinical response to
inﬂiximab during the 30-week treatment period). All ten
patients fulﬁlled the American College of Rheumatology
criteria for RA revised in 1987 [13]. They all had active
arthritis as deﬁned by the 28-joint disease activity score
(DAS28) [3.2 at study entry, with the exception of one
patient who wanted to receive MZR therapy despite a
DAS28 of 3.0. The mean ± standard deviation (SD) age of
the patients was 50.3 ± 12.8 years, the mean ± SD disease
duration was 6.5 ± 6.2 years, and the mean ± SD DAS28
using erythrocyte sedimentation rate (ESR; DAS28-ESR)
was 5.0 ± 1.5.
All patients were concomitantly receiving MTX,
6–8 mg/week. The doses of concomitant prednisolone and
DMARDs, including MTX, were not increased during the
last 3 months prior to entry in the study.
Study protocol and clinical response
This study was approved by the ethical committee of our
hospital. Informed consent was obtained before the study.
Patients ﬁrst received 100 mg of MZR together with MTX.
The patients received 300 mg MZR on the ﬁrst two days of
the week: 200 mg MZR on the ﬁrst day in two divided
doses and 100 mg MZR in one dose on the second day
(Fig. 1). At the time of each infusion of inﬂiximab, the
swollen joint count (SJC), tender joint count (TJC), visual
analogue score (VAS), ESR, and DAS28 were recorded.
Five of the ten patients were started on MZR pulse therapy
between the infusions of inﬂiximab. We therefore we
assessed the patients’ DAS28 at baseline and after
12–16 weeks, 20–24 weeks and, thereafter, every 8 weeks.
Statistical analysis
We analyzed data using the Student’s t test to assess
whether the changes in DAS28 and laboratory data from
baseline during the course of the treatment were signiﬁcant.
Results
The clinical socio-demographic and clinical characteristics
of the patients, including previously administered
DMARDs (as well as those drugs continued during the
study), response to MZR pulse therapy [according to the
EULAR (European League Against Rheumatism) response
criteria at weeks 12–16, and weeks 20–24], response to
inﬂiximab (according to the EULAR response criteria at
week 30), and change in the dose of prednisolone (PSL)
between baseline and week 24, are shown in Table 1.
All of the patients were followed for more than
24 weeks. The MZR pulse therapy was well tolerated, and
none of the patients discontinued the therapy. Seven
patients (70%) had achieved a moderate or good EULAR
response at weeks 12–16, and ﬁve patients (50%) had
achieved a moderate or good EULAR response at weeks
20–24,.
The mean DAS28 decreased from 5.0 at baseline to 3.9
(P = 0.047) at week 16, and 4.1 (P = 0.043) at week 24
(Fig. 2). The mean C-reactive protein (CRP) and ESR
levels decreased, although not signiﬁcantly during MZR
pulse therapy.
Fig. 1 The schedule of mizoribine (MZR) pulse therapy, consisting
of combination drug therapy with 100 mg methotrexate (MTX). Total
drug therapeutic program was 8 mg/week of MTX
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to MZR pulse therapy after 24 weeks; we therefore
increased the dose of MZR up to 150 mg in these patients.
One of these patients showed a favorable response to the
higher dose (case 2). None of the patients had an adverse
reaction to the higher dose, not even a minor infection, nor
were there any abnormalities in the laboratory data. A
complete blood count, including white blood cells, neu-
trophils, lymphocytes, hemoglobin, and platelet counts,
demonstrated the absence of any signiﬁcant changes that
could be related to MZR pulse therapy (Table 2).
Two successful cases of MZR pulse therapy are
described below in detail.
Case 1 was a 48-year-old woman who had been suc-
cessfully treated with 10 mg/kg of inﬂiximab during a
clinical trial for 54 weeks. Her DAS28 had been less than
2.6 during the trial, but inﬂiximab therapy was stopped
after the eighth infusion because the trial was ﬁnished.
Thereafter, her disease activity increased, (DAS28 3.7),
and inﬂiximab therapy was restarted at a dose of 2.6 mg/kg
(the maximum approved dose is 200 mg and her body
weightwas77 kg;therefore,shewasadministered2.6 mg/kg
inﬂiximab). However, her disease activity did not decrease
despite three additional infusions of inﬂiximab. We there-
fore considered that 2.6 mg/kg inﬂiximab had limited
efﬁcacy in this patient and added MZR pulse therapy at
a dose of 100 mg together with MTX. By 4 weeks after
the iniation of the MZR pulse thereapy, her DAS28 had
decreased to 2.4. At week 20 on MZR pulse therapy, she
achieved a good EULAR response (Fig. 3).
Case 2 was a 64-year-old man whose disease had been
successfully controlled with inﬂiximab, but who showed an
increase of the disease activity while still on this drug. We
therefore added MZR pulse therapy at a dose of 100 mg
together with MTX 4 weeks before the 19th infusion of
inﬂiximab. Twenty weeks later, his DAS28 had decreased
to 3.0 ,and he had achieved a good EULAR response.
Thereafter, his disease activity was under control for over
24 weeks. At the time of the 25th infusion of inﬂiximab,
his DAS28 was 5.4, and his disease activity had increased
again. We then increased the dose of MZR to 150 mg.
Eight weeks later, his DAS28 had decreased to 3.5 (Fig. 4).
This second case suggests that increasing the dose of
MZR may be effective. The clinical response to MZR pulse
therapy was most clearly observed in cases 1 and 2,
probably because inﬂiximab showed some degree of efﬁ-
cacy in these patients. In case 4, although the patient’s
DAS28 did not decrease until week 24 of treatment, MZR
pulse therapy was considered to be clinically effective
because we were able to decrease the dose of PSL from 8 to
3 mg.
Discussion
In Japan, inﬂiximab has been used to treat RA patients
since 2003. Although it efﬁcacy in Japanese RA patients
was demonstrated in the RECONFIRM study [14], the
results of this study also indicated that the clinical response
to inﬂiximab may decline after 30 weeks of drug therapy.
Table 1 Clinical and socio-demographic characteristics of the patient cohort
Case
no.
Sex Age
(years)
Duration of
RA (years)
Stage
a Previous
DMARDs
b
Response
to IFX
c
Baseline
DAS28
d
Response to MZR
e/
DAS28 (weeks 12–16)
Response to MZR/
DAS28 (weeks 20–24)
Dose of
predonisolone
1 M 64 8 II SASP BC Moderate 7.9 Good 3.0 Moderate 4.5 No change
2 F 48 4 III SASP BC Good 4.0 Good 2.5 Good 2.5 No change
3 F 32 2.5 II SASP BC Good 4.8 Moderate 4.2 No 4.7 No change
4 F 41 1.5 I SASP BC Moderate 6.9 No 7.3 No 7.3 8 ? 3m g
5 F 55 2.5 II SASP BC No 5.2 Moderate 4.2 Moderate 4.3 8 ? 7m g
6 M 29 20 IV SASP BC D-PC No 4.1 Moderate 3.4 No 4.2 No change
7 F 65 2 I SASP BC Moderate 3.0 No 3.1 No 2.8 No change
8 M 59 1 I SASP Good 3.8 Moderate 2.9 No 3.3 No change
9 F 50 11 IV SASP BC GST Good 4.2 No 3.9 Good 2.7 10 ? 8m g
10 M 60 12 II BC Moderate 5.6 Moderate 4.3 Moderate 5.0 No change
RA rheumatoid arthritis, IFX inﬂiximab, MZR mizoribine
a Steinbrocker stage of radiographs
b Disease-modifying antirheumatic drugs, including drugs continued during the study. SASP salazosulfapyridine, BC bucillamine,
D-PC D-penicillamine, GST gold sodium thiomalate
c EULAR (European League Against Rheumatism) response criteria, at week 30
d DAS28-ESR, 28-joint disease activity score based on erythrocyte sedimentation rate
e EULAR response criteria
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development of human antichimeric antibody against inf-
liximab (HACA) has been reported in several studies
[15, 16]. An increase of the dose of inﬂiximab beyond
3 mg/kg (e.g., 5, 10 mg/kg) or the shortening of the
interval between inﬂiximab infusions (e.g., every 6 weeks)
has proven to be effective in such cases [2, 17, 18].
However, these methods are not approved by the Japanese
Ministry of Health, Labor and Welfare. Etanercept is
another biological product available in Japan. Alternating
anti-TNF therapies, such as switching between etanercept
and inﬂiximab, has been reported to be effective in patients
who do not respond to their ﬁrst anti-TNF drug [19, 20].
However, such switching of anti-TNF therapy was strictly
limited in Japan because only two biologics were available
when we started this study. Tocilizumab and adalimumab
were approved in Japan in April 2008, thereby doubling the
number of biologics that can be used to treat patients with
RA (four); however, the choice of biologics is still limited
because some patients refuse self-injection. In our opinion,
Fig. 2 a Changes in the 28-joint disease activity score (DAS28)
from baseline and during the MZR pulse therapy regimen, at weeks
4–8, 12–16, and 20–24. The DAS28 signiﬁcantly decreased
at 12–16 weeks (P = 0.047) and at 20–24 weeks (P = 0.043).
b Change in the tender joint count (TJC) at baseline and during
therapy, at 4–8, 12–16, and 20–24 weeks. c Change in the swollen
joint count (SJC) at baseline and during therapy, at 4–8, 12–16, and
20–24 weeks. d Change in the erythrocyte sedimentation rate (ESR)
at baseline and during therapy, at 4–8, 12–16, and 20–24 weeks.
e Change in the C-reactive protein (CRP) at baseline and during
therapy, at 4–8, 12–16, and 20–24 weeks. f Change in the visual
analog scale (VAS) at baseline and during therapy, at 4–8, 12–16, and
20–24 weeks. NS Not signiﬁcant
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123it is better to use one biological agent as long as possible—
and not a combination—because it is still unclear whether
the other biologics decrease the effect.
The objective of this study was to evaluate the efﬁcacy
and safety of MZR pulse therapy in patients who showed a
reduced or insufﬁcient response to inﬂiximab. We observed
signiﬁcant efﬁcacy at weeks 12–16 and at weeks 20–24.
The decrease in the number of patients who responded to
the therapy at weeks 20–24 (relative to weeks 12–16) may
suggest a decline in the response of our patients to MZR
pulse therapy. In this situation, a higher dose of MZR
combined with MTX may be effective, as shown in case 1.
Further studies are needed to conﬁrm the efﬁcacy of the
higher dose of MZR.
The response rate using MZR pulse therapy that we
obtained in this study in patients who showed a reduced
response to inﬂiximab (70%; 7/10 patients with a moderate
or good EULAR score) was higher than that reported in
previous studies using MZR pulse therapy (16–50%) in
patients who showed inadequate response to MTX (without
inﬂiximab) [9–11]. This difference in response rate sug-
gests that MZR pulse therapy may have some additional
effect other than that as a DMARD. Although we could not
measure anti-inﬂiximab antibody levels, it would appear
that MZR pulse therapy administered concomitantly with
inﬂiximab, in addition to its effect as a DMARD, also
inhibits HACA.
In conclusion, in our small study cohort of patients with
RA, MZR pulse therapy proved to be effective in patients
who showed a reduced response to inﬂiximab. We suggest
that, in cases where inﬂiximab is ineffective, MZR pulse
therapy should be attempted before the patient is switched
to another biologic.
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